{
    "organizations": [],
    "uuid": "e448287ff54d943c32f2a07592ba18bb8e8fd912",
    "author": "",
    "url": "https://www.reuters.com/article/brief-selecta-biosciences-says-expects-t/brief-selecta-biosciences-says-expects-to-report-initial-results-for-phase-2-clinical-trial-of-sel-212-in-chronic-severe-gout-in-april-2018-idUSFWN1P30QM",
    "ord_in_thread": 0,
    "title": "BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "#Market News January 8, 2018 / 1:45 PM / in 14 minutes BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Selecta Biosciences Inc: \n* SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING \n* SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019 Source text ( bit.ly/2EnEbTQ ) Further company coverage:",
    "published": "2018-01-08T15:44:00.000+02:00",
    "crawled": "2018-01-08T16:12:17.052+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "january",
        "pm",
        "minute",
        "bioscience",
        "say",
        "expects",
        "report",
        "initial",
        "result",
        "phase",
        "clinical",
        "trial",
        "chronic",
        "severe",
        "gout",
        "april",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "selecta",
        "bioscience",
        "inc",
        "selecta",
        "bioscience",
        "say",
        "expects",
        "report",
        "initial",
        "result",
        "phase",
        "clinical",
        "trial",
        "chronic",
        "severe",
        "gout",
        "april",
        "sec",
        "filing",
        "selecta",
        "bioscience",
        "expects",
        "submit",
        "investigational",
        "new",
        "drug",
        "application",
        "methylmalonic",
        "acidemia",
        "source",
        "text",
        "company",
        "coverage"
    ]
}